CA2438030A1 - Methode de diagnostic de l'angiogenese, preparations et methodes d'identification par criblage de modulateurs de l'angiogenese - Google Patents

Methode de diagnostic de l'angiogenese, preparations et methodes d'identification par criblage de modulateurs de l'angiogenese Download PDF

Info

Publication number
CA2438030A1
CA2438030A1 CA002438030A CA2438030A CA2438030A1 CA 2438030 A1 CA2438030 A1 CA 2438030A1 CA 002438030 A CA002438030 A CA 002438030A CA 2438030 A CA2438030 A CA 2438030A CA 2438030 A1 CA2438030 A1 CA 2438030A1
Authority
CA
Canada
Prior art keywords
angiogenesis
protein
sequence
nucleic acid
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002438030A
Other languages
English (en)
Inventor
Richard Murray
Richard Glynne
Susan R. Watson
Natasha Aziz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2438030A1 publication Critical patent/CA2438030A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des méthodes et des préparations pouvant être utilisées pour le diagnostic et le traitement de phénotypes angiogénique et de maladies associées à l'angiogenèse. L'invention porte également sur des méthodes pouvant être utilisées pour l'identification de modulateurs de l'angiogenèse.
CA002438030A 2001-02-14 2002-02-14 Methode de diagnostic de l'angiogenese, preparations et methodes d'identification par criblage de modulateurs de l'angiogenese Abandoned CA2438030A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US78435601A 2001-02-14 2001-02-14
US09/784,356 2001-02-14
US79139001A 2001-02-22 2001-02-22
US09/791,390 2001-02-22
US28547501P 2001-04-19 2001-04-19
US60/285,475 2001-04-19
US31002501P 2001-08-03 2001-08-03
US60/310,025 2001-08-03
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US33424401P 2001-11-29 2001-11-29
US60/334,244 2001-11-29
PCT/US2002/004915 WO2002079492A2 (fr) 2001-02-14 2002-02-14 Methode de diagnostic de l'angiogenese, preparations et methodes d'identification par criblage de modulateurs de l'angiogenese

Publications (1)

Publication Number Publication Date
CA2438030A1 true CA2438030A1 (fr) 2002-10-10

Family

ID=27559580

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002438030A Abandoned CA2438030A1 (fr) 2001-02-14 2002-02-14 Methode de diagnostic de l'angiogenese, preparations et methodes d'identification par criblage de modulateurs de l'angiogenese

Country Status (5)

Country Link
EP (1) EP1418943A1 (fr)
JP (1) JP2004531249A (fr)
AU (1) AU2002257004A1 (fr)
CA (1) CA2438030A1 (fr)
WO (1) WO2002079492A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
JP2004518437A (ja) 2000-10-25 2004-06-24 ディアデクサス インコーポレーテッド 肺特異的遺伝子およびタンパク質に関する組成物および方法
US7622443B2 (en) 2002-04-26 2009-11-24 California Institute Of Technology Method for inhibiting pro-angiogenic activities of endothelial cells selectively at a site of neoangiogenesis in a mammal by administration of the extracellular domain of D1-1 polypeptides
WO2003091447A2 (fr) 2002-04-26 2003-11-06 California Institute Of Technology Acides nucleiques d1-1, polypeptides et methodes associees
WO2004024063A2 (fr) * 2002-09-11 2004-03-25 Genentech, Inc. Compositions et procede de diagnostic et de traitement des tumeurs
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
JP2007525167A (ja) * 2003-04-01 2007-09-06 ジェンザイム・コーポレーション 乳房内皮細胞発現パターン
US20060216286A1 (en) 2003-04-25 2006-09-28 Yasuaki Ito Novel screening method
US7267950B2 (en) * 2003-05-01 2007-09-11 Veridex, Lcc Rapid extraction of RNA from cells and tissues
US9309323B2 (en) 2003-06-09 2016-04-12 The University Of British Columbia Methods for detecting and treating cancer
WO2004109286A2 (fr) * 2003-06-09 2004-12-16 The University Of British Columbia Procedes de detection et de traitement du cancer
US20070105169A1 (en) * 2003-06-30 2007-05-10 Lydie Bougueleret Secreted polypeptide species associated with cardiovascular disorders
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
DE10340373A1 (de) * 2003-08-30 2005-03-24 Henkel Kgaa Verfahren zur Bestimmung von Haarzyklus-Marken
JP2005073621A (ja) * 2003-09-01 2005-03-24 Japan Science & Technology Agency 脳腫瘍マーカーと脳腫瘍の診断方法
WO2005069855A2 (fr) * 2004-01-13 2005-08-04 Rigel Pharmaceuticals, Inc. Modulateurs d'angiogenese
DK1755659T3 (da) 2004-03-24 2012-02-27 Abbott Biotherapeutics Corp Anvendelse af anti-alfa5beta1-antistoffer til inhibering af kræftcelleproliferation
WO2005103283A1 (fr) 2004-04-23 2005-11-03 Takeda Pharmaceutical Company Limited Nouveau procédé de criblage
WO2005113788A2 (fr) * 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics et therapeutiques pour des maladies associees a la kinase 6 associee au recepteur couple a une proteine g (grk6)
ATE543914T1 (de) * 2005-09-01 2012-02-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegen vegfr2 modulator.
JP2009526861A (ja) * 2006-02-14 2009-07-23 ゲイシンガー クリニック 血管新生標的としてのｇｐｃｒ
EP1987359B1 (fr) * 2006-02-22 2015-03-18 Philogen S.p.A. Marqueurs de tumeurs vasculaires
NZ615012A (en) 2006-03-21 2015-11-27 Genentech Inc Combinatorial therapy involving alpha5beta1 antagonists
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
JP5308328B2 (ja) 2006-04-04 2013-10-09 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
MY151191A (en) 2007-09-26 2014-04-30 Genentech Inc Novel antibodies
WO2010080769A2 (fr) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Procédés et compositions chimiothérapeutiques
EP2216399A1 (fr) * 2009-01-30 2010-08-11 Université de la Méditerranée CD146 humaine soluble, preparation et utilisations
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
WO2010144358A1 (fr) 2009-06-08 2010-12-16 Singulex, Inc. Groupes de biomarqueurs très sensibles
US8828387B2 (en) 2009-07-08 2014-09-09 Actgen Inc Antibody having anti-cancer activity
SG178845A1 (en) 2009-08-21 2012-04-27 Gilead Biologics Inc Catalytic domains from lysyl oxidase and loxl2
WO2011027132A1 (fr) 2009-09-03 2011-03-10 Cancer Research Technology Limited Inhibiteurs de clec14a

Also Published As

Publication number Publication date
JP2004531249A (ja) 2004-10-14
WO2002079492A8 (fr) 2004-03-25
WO2002079492A2 (fr) 2002-10-10
AU2002257004A1 (en) 2002-10-15
EP1418943A1 (fr) 2004-05-19

Similar Documents

Publication Publication Date Title
CA2438030A1 (fr) Methode de diagnostic de l'angiogenese, preparations et methodes d'identification par criblage de modulateurs de l'angiogenese
US7736853B2 (en) Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer
US7435589B2 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US6682890B2 (en) Methods of diagnosing and determining prognosis of colorectal cancer
CA2459219A1 (fr) Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
CA2477043A1 (fr) Nouveaux procedes de diagnostic du cancer colorectal metastatique, compositions et procedes de criblage des modulateurs du cancer colorectal metastatique
CA2453098A1 (fr) Procede de diagnostic du cancer de la vessie, compositions et procedes de criblage de modulateurs du cancer de la vessie
US20030124579A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20040253606A1 (en) Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20030232350A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2451465A1 (fr) Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien
US20100297152A1 (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
CA2444691A1 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
CA2425569A1 (fr) Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
US6750013B2 (en) Methods for detection and diagnosing of breast cancer
CA2440703A1 (fr) Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein
US20030228570A1 (en) Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
CA2381699A1 (fr) Nouvelles techniques de diagnostic de l'angiogenese, compositions et techniques de criblage pour modulateurs d'angiogenese
US20070059748A1 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2369319A1 (fr) Methodes permettant de diagnostiquer du cancer colo-rectal, compositions, et methodes permettant de detecter des modulateurs du cancer colo-rectal
US6455668B1 (en) Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US20030108926A1 (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US20030157544A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
WO2003081250A1 (fr) Compositions et procedes utilisables, pour le cancer, en association avec une expression modifiee du recepteur de la prolactine (prlr)
CA2431313A1 (fr) Procede de diagnostic du cancer du sein et/ou du cancer colorectal, compositions, et procedes de criblage de modulateurs du cancer du sein et/ou du cancer colorectal

Legal Events

Date Code Title Description
FZDE Discontinued